key: cord-1009874-cwv0lfow authors: Wahezi, Dawn M.; Lo, Mindy S.; Rubinstein, Tamar B.; Ringold, Sarah; Ardoin, Stacy P.; Downes, Kevin J.; Jones, Karla B.; Laxer, Ronald M.; Pellet Madan, Rebecca; Mudano, Amy S.; Turner, Amy S.; Karp, David R.; Mehta, Jay J. title: American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 1 date: 2020-07-23 journal: Arthritis Rheumatol DOI: 10.1002/art.41455 sha: 1652d8c3306cfa2c316c6c2eacd86638276113f4 doc_id: 1009874 cord_uid: cwv0lfow OBJECTIVE: To provide clinical guidance to rheumatology providers who treat children with PRD in the context of the COVID‐19 pandemic. METHODS: The task force, consisting of 7 pediatric rheumatologists, 2 pediatric infectious disease physicians, one adult rheumatologist and one pediatric nurse practitioner, was convened on May 21, 2020. Clinical questions and subsequent guidance statements were drafted based on review of queries posed by patients, families and healthcare providers of children with PRD. An evidence report was generated and disseminated to task force members to assist with three rounds of asynchronous, anonymous voting by email using a modified Delphi approach. Voting was completed using a 9‐point numeric scoring system with predefined levels of agreement (“disagreement”; “uncertain”; “agreement”) and consensus. To be approved as a guidance statement, median votes were required to fall into the highest tertile for agreement with “moderate” (M) or “high” (H) levels of consensus. RESULTS: 33 guidance statements were drafted and voted upon during rounds two and three of voting. Of these statements, all received median votes within the highest tertile of agreement and were associated with moderate (n=6) or high consensus (n=27). Statements with similar recommendations were combined, resulting in 27 final guidance statements. CONCLUSION: These guidance statements have been generated based on review of the available literature, indicating that children with PRD do not appear to be at increased risk for susceptibility to SARS‐CoV‐2 infection. This guidance is presented as a “living document,” recognizing that the literature on COVID‐19 is rapidly evolving, with future updates anticipated. been shown to be highly reproducible (7) and was successfully applied by the ACR COVID-19 Clinical Guidance Task Force in the development of guidance statements for adult patients with RD (2). A 9-point scale was used by task force members to rate each of the statements. A score of 9 was considered to be the highest level of appropriateness while a score of 1 indicated the statement was entirely inappropriate. Prior to voting, median scores of 1-3 were defined as inappropriate, 4-6 as uncertain, and 7-9 as appropriate. Consensus was pre-specified as high (H) if all 11 votes coalesced within the same tertile, while low (L) consensus occurred when voting was dispersed along the 9point scale (with ≥3 votes in the 1-3 range and ≥3 votes in the 7-9 range). Moderate (M) consensus encompassed all other scenarios. The votes of each task force member were counted equally and tallied. The results of the initial voting were distributed to the task force and reviewed during a 90minute webinar on June 3, 2020. Statements that were rated as uncertain (median score 4-6) and/or characterized by moderate or low consensus were addressed first. The panelists were then encouraged to discuss the remaining statements. Rounds two and three voting. Input from the initial voting and discussion was incorporated into the draft guidance statements (DW, JM), and the document was re-distributed to the entire task force for a second round of voting. Voting in this phase was conducted in the same manner as described above, and results were reviewed at a third webinar on June 11, 2020. Guidance statements that earned a median score of 7-9 with moderate or high levels of consensus during the second round of voting were approved by the panel. Guidance statements under the domain of patients with PRD and probable or confirmed SARS-CoV-2 infection were initially dichotomized by "asymptomatic/mild" disease and "moderate/severe" disease. After further discussion, the task force agreed that dichotomizing by "asymptomatic" and "symptomatic" would be more representative of current clinical practice related to viral illnesses in children with PRD. Seven statements were subsequently redefined and sent back to task force members for a third round of voting using similar methods. Guidance Approval. Following the final webinar, approved statements were refined and, in some instances, combined into 27 final guidance statements to reduce redundancy. A preliminary Accepted Article guidance document was generated, and the entire task force was given an opportunity to review and edit the document. Approval was obtained from each panelist on June 15, 2020 and by the ACR Board of Directors on June 17, 2020 Of the 119 original clinical questions considered in the first round of voting, median votes on 44 questions indicated uncertainty (4 to 6), with 5 questions determined to be low consensus based on predefined thresholds. Clinical questions were reviewed and subsequently excluded if thought to be out of the scope of this task force (e.g., questions related to MIS-C) or if determined to have too much uncertainty and/or lack of sufficient evidence to allow for the drafting of a clinical guidance statement at this time (e.g. questions related to SARS-CoV-2 vaccine). The remaining questions were combined by common themes, drafted into 33 guidance statements and voted upon during rounds two and three (Supplemental Tables 1-3) . Of these 33 statements, all received median votes of 7, 8 or 9 and were associated with moderate (n=6) or high consensus (n=27). Statements with similar recommendations were combined, resulting in 27 final guidance statements posted online by the ACR in a clinical guidance summary on June 18, 2020. Approaches to risk reduction. General guidance statements regarding patients with PRD are presented in Table 2 . To date, there is little evidence to suggest a higher risk for severe COVID-19 in children with PRD (8) (9) (10) (11) (12) or in children receiving immunomodulatory therapies commonly used for PRD (13) (14) (15) . Among the published series of hospitalized children with COVID-19, there have been no reports of severe illness in children with PRD (4, 16) . Similarly, preliminary data from the Global Rheumatology Alliance patient survey reported only 5 cases of COVID-19 in children with PRD, none of whom were hospitalized (17). The Childhood Arthritis and Rheumatology Research Alliance (CARRA) patient registry is currently collecting data on the prevalence of COVID-19 among children This article is protected by copyright. All rights reserved with PRD, with results yet to be reported. Based on available evidence, the task force members agreed that children and families of children with PRD should be counseled on preventative measures similar to the general population, including adequate hand washing, social distancing, masking/facial covering (in children over 2 years of age) and disinfecting of frequently touched surfaces. In geographic areas with high incidence of COVID-19, particularly during periods of increased community transmission, children with PRD should adhere to local public health social distancing recommendations and limit close contact with others outside their household. The task force additionally discussed issues concerning safe return to schools, camps, daycare and college. In general, the task force agreed that there may not be unique preventative measures for children with PRD apart from those recommended for all other children, however this was not formulated into a formal recommendation due to ongoing uncertainties about the evolving pandemic. Families should refer to local school guidance, as well as the most current CDC (18) and AAP recommendations (19) to best address the needs of their individual child. The task force also recognized that caregivers of children with PRD may be at risk for occupational exposures that increase risk of acquiring COVID-19. Rheumatology providers should counsel families to refer to CDC guidelines for specific occupations (20) and the Occupational Safety and Health Administration (OSHA) (21) for guidance to protect themselves from occupational exposure to SARS-CoV-2. Caregivers should discuss with employers the need for adequate social distancing, masking/facial covering, daily health checks and consider options for working from home (22). Antibody testing for SARS-CoV-2 was not recommended at this time, due to assay variability and lack of sufficient evidence to support its utility in informing individuals on their personal risk of reinfection or the safety of returning to school or the workplace (23, 24) . Providers should also be aware that, as the prevalence of antibodies to SARS-CoV-2 increases in the general population, routine serologic testing may result in false positive antibody detection in patients with PRD receiving intravenous immunoglobulin (IVIG). Ongoing clinical management. Shared decision making should occur between patients, families and rheumatology providers to discuss additional measures to reduce interruptions in clinical care, particularly during periods of increased community transmission. Such measures may include This article is protected by copyright. All rights reserved use of telemedicine for routine, regularly scheduled and non-urgent clinical assessments, and physical therapy. The American Telemedicine Association has "Operating Procedures for Pediatric Telehealth" (endorsed by the AAP), which serve as an operational reference and educational tool regarding appropriate telehealth care for pediatric patients (25). For ophthalmologic surveillance in children at high risk for chronic uveitis or personal history of uveitis, the task force agreed that ongoing in-person ophthalmology evaluation is strongly recommended due to risk of asymptomatic uveitis and the long-term sequelae that can result from undetected uveitis (26). The task force agreed that all patients with PRD should receive routine vaccinations (unless contraindicated), including the annual influenza vaccine, on or as close to schedule as possible. Given concerns about ongoing transmission of COVID-19 during influenza season, administration of the seasonal influenza vaccine is strongly recommended to limit simultaneous viral outbreaks, possible co-infections, increased hospitalizations and risks of exceeding hospital capacities. Other considerations. The task force also recognized the increased prevalence of anxiety and depression in patients with PRD compared to the general population (27) (28) (29) and concerns about additional emotional distress related to the COVID-19 pandemic (30) . Rheumatology providers should be aware of the heightened emotional burden posed by the pandemic, including fears of becoming infected, having a family member infected, potential risks from medications, concerns about social isolation and potential financial hardships. Providers should educate caregivers and patients about means to reduce anxiety, including referrals for telehealth or in-person mental health counselling when appropriate (31, 32). General treatment recommendations. The task force unanimously agreed that primary control of underlying rheumatic disease is of utmost importance, recognizing that flares of PRD may increase the need for immunosuppression and lead to increased contact with health care systems. In addition, active inflammatory disease may independently increase infection risk in patients with RD due to This article is protected by copyright. All rights reserved immune dysregulation (9, 12, 33-35), thus guidance recommendations were targeted to limit medication disruptions. Recognizing that data are still limited, our task force did not identify current evidence to suggest that non-steroidal anti-inflammatory drugs (NSAIDs), hydroxychloroquine (HCQ), angiotensin converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARBs), colchicine, conventional disease modifying anti-rheumatic drugs (cDMARDs), biologic DMARDs (bDMARDs) or targeted synthetic DMARDS (tsDMARDs) contribute to increased susceptibility to SARS-CoV-2 infection (13) (14) (15) . Despite initial warnings that NSAIDs and ACEi/ARBs might contribute to worse outcomes in COVID-19, we found no clinical data to substantiate these concerns in adults (36, 37) . Similar to ACR guidance for the management of adult patients with RD, our task force supported the continued use of immunomodulatory medications in patients with PRD who do not have known SARS-CoV-2 exposure or infection (2). Guidance statements for this group are presented in Table 3 . Likewise, for patients with newly diagnosed or worsening PRD, initiation of DMARD therapy was recommended in order to adequately control PRD (38, 39) . The task force also recognized that alternative treatment plans for intravenous medications may need to be considered during periods of increased community transmission of SARS-CoV-2 and when safe access to the hospital may be challenging. In these scenarios, home infusions of medications or transition to oral or subcutaneous maintenance therapies may be considered, when appropriate. The task force also discussed plans for de-escalation of therapy for patients who remain in clinical remission on medications. While the task force agreed that patients should not be kept on prolonged immunomodulatory therapy unnecessarily, shared decision making amongst patients, families and providers was recommended to discuss potential consequences of withdrawing medications, including risks of disease flare, followed by a need for increased in-person visits, laboratory monitoring, and potentially the need for escalation of therapy (including the use of glucocorticoids) (40) (41) (42) . Special considerations for cyclophosphamide and rituximab. For patients requiring cyclophosphamide or rituximab for control of their PRD, the task force recommended continuing current management to adequately control underlying disease and prevent potentially life and/or organ threatening manifestations. Children requiring cyclophosphamide therapy may be at significant risk This article is protected by copyright. All rights reserved for infection due to underlying diagnosis, treatment-induced leukopenia/lymphopenia and concomitant use of glucocorticoids (43) (44) (45) . Given that cyclophosphamide is reserved only for patients who have life and/or organ threatening disease, the task force agreed that benefits of treatment likely outweigh the risks in this scenario. Special considerations for glucocorticoids. The task force acknowledged the mixed data regarding the potential immunosuppressive effects of glucocorticoids in adults with infection from SARS-CoV-2. Glucocorticoids may increase risk of secondary infection and delay viral clearance. Prior studies have shown little benefit from the use of glucocorticoids in the treatment of SARS-CoV-1, Middle East Respiratory Syndrome (MERS), influenza or respiratory syncytial virus (RSV) (46) (47) (48) . However, glucocorticoids have also been used to treat the inflammatory sequelae of COVID-19, including acute respiratory distress syndrome, hyperinflammation and cytokine storm, with reports of improved survival, shorter duration of oxygen supplementation and shorter intensive care unit (ICU) stays in adults (49) (50) (51) . Data regarding the risks and benefits of glucocorticoids in COVID-19 is rapidly evolving. When considering patients with PRD on chronic glucocorticoids, there is little evidence to date to suggest that glucocorticoid use increases the risk of acquiring SARS-CoV-2 infection. A preliminary analysis of the first 600 cases in the Global Rheumatology Alliance COVID-19 Registry indicated that hospitalization risk increased among adult rheumatology patients diagnosed with COVID-19 who were taking daily prednisone doses in excess of 10mg, after accounting for disease activity (52). Thus, the task force recommended that glucocorticoids be continued or initiated when clinically indicated, using the lowest effective dose to control underlying PRD. Given that weightbased dosing strategies (calculated by mg/kg) are most appropriate for pediatric patients, the task force concluded that defining a specific dose (e.g., less than or equal to 10mg prednisone) could not be directly applied to the pediatric population. The task force further acknowledged that higher dose oral glucocorticoids (greater than or equal to 2 mg/kg/day prednisone equivalent) or intravenous "pulse" glucocorticoids (greater than or equal to 10 mg/kg/day methylprednisolone equivalent) may be indicated in the setting of severe life and/or organ threatening clinical manifestations from underlying PRD and should not be withheld. This article is protected by copyright. All rights reserved Additionally, the task force emphasized that patients receiving oral glucocorticoids (> 5 mg/day prednisone equivalent) are at risk for adrenal suppression (53) and recommends avoidance of abrupt withdrawal of glucocorticoids, keeping in mind potential need for stress dose glucocorticoids in certain clinical scenarios. When considering intra-articular corticosteroid injections, the task force deemed the risk of systemic immunosuppression minimal and supported proceeding with injections when needed, understanding that access may be limited during times of increased community transmission of SARS-CoV-2. Ongoing evaluations and clinical care. Routine laboratory monitoring during the pandemic was discussed. While it is recognized that medication monitoring typically occurs at regularly scheduled intervals (54) , these intervals may be modestly extended in patients with PRD who have stable disease, stable medications and no prior history of laboratory abnormalities associated with medication toxicity. In contrast, the task force concluded that laboratory monitoring for disease activity should continue at usual intervals, particularly during times of limited access to in-person clinical evaluations. Recognizing that current data are insufficient to define precisely the duration of time that constitutes a prolonged exposure, the CDC has created an operational definition, reported as an interaction with a person known to have COVID-19 for more than 15 minutes at a distance of less than 6 feet without both parties wearing masks (55). Shorter interactions may additionally be relevant depending on symptoms and type of interaction. As previously discussed, recent data in both adults with RD and children with PRD do not suggest an increased risk of susceptibility to COVID-19. Similar to the guidance statements provided in Table 3 , our task force agreed that current immunomodulatory medications may be continued after COVID-19 exposure while monitoring for fever or other symptoms of COVID-19 (Table 4 ). The task force also agreed that low to moderate Accepted Article dose glucocorticoids could be continued to control underlying PRD after exposure, with an effort to reduce dose when possible. Given the recommended 14-day monitoring period after exposure, the task force recommended that high dose oral or intravenous "pulse" glucocorticoids be delayed when feasible, except in the scenario of life and/or organ threatening disease. Cases of asymptomatic SARS-CoV-2 infection. Although the exact prevalence is unknown, a proportion of children may be asymptomatic despite a positive PCR test for SARS-CoV-2 (56-59). With increased availability of testing and recommendations for PCR screening prior to elective surgeries and procedures, cases of children with asymptomatic COVID-19 may be encountered (60) . To date, there are no data to suggest that continued use of immunomodulatory medications in infected, asymptomatic children with PRD alters the clinical course of SARS-CoV-2 infection. Thus, the benefits of continuing immunomodulatory medications in these scenarios appear to outweigh the risks (Table 5a) . As noted previously, these recommendations have been generated to support shared decision making between providers and patients and families, and cases need to be considered on an individual basis. Asymptomatic cases should be counseled to quarantine per CDC guidelines and to contact their provider immediately should symptoms of COVID-19 develop (61). to moderate symptoms, with only a small percentage requiring hospitalization (59) . Data from two major epicenters of disease in the United States (New York and Washington DC) reported that 28% and 20% of children and young adults admitted to the hospital with SARS-CoV-2 infection developed severe disease and required respiratory support (4, 16) ; neither of the reports included patients with PRD or on baseline DMARD therapy. Similarly, cases of children on immunomodulatory therapies commonly used in PRD, have not shown increased severity of disease (13) (14) (15) . Despite reassuring data that patients with RD on immunomodulatory therapy do not appear to have more severe infection from SARS-CoV-2 (9), the task force did not think there was sufficient literature at this time to support a recommendation to continue medications in the context of symptomatic COVID-19 This article is protected by copyright. All rights reserved infection (Table 5b) . These recommendations were congruent with conventional clinical practice to hold immunosuppressive therapy in children with PRD and a concurrent infection. Recognizing that much of the morbidity and mortality of COVID-19 may be related to an individual host immune response and hyperinflammation, several authors have also suggested that maintaining immune regulation in patients with RD may provide additional benefit and reduce risk of severe disease (9, 12, 34) . Selective inhibitors of IL-1 and IL-6 have additionally been investigated in the treatment of COVID-19 hyperinflammation (62-67). This observation, coupled with the knowledge that children with autoinflammatory PRD, such as periodic fever syndromes or systemiconset juvenile idiopathic arthritis, may be particularly sensitive to medication disruptions, led the task force to recommend that colchicine, IL-1 and IL-6 inhibitors may be continued, even in the context of symptomatic COVID-19 infection. Selective IL-1 inhibitors have been used safely in the setting of other infections and in sepsis trials (68) . In contrast, IL-6 inhibitors may be associated with increased risk of secondary infections, thus appropriateness of therapy in individual cases should be reviewed. Janus kinase (JAK) inhibitors have also been investigated as potential therapies in the management of COVID-19 hyperinflammation (35, 69) . However, inhibition of interferon (IFN) signaling through the use of JAK inhibitors has been suggested to dampen the innate antiviral response potentially worsening the host response to viral infection (70) . In the absence of robust data regarding the safety of JAK inhibitors in the context of symptomatic SARS-CoV-2 infection, the taskforce recommended temporarily holding tsDMARDs. Irrespective of the COVID-19 pandemic, the overall goals of treatment in patients with PRD remain prompt control of active disease, relief of symptoms, prevention of long-term sequelae and efforts to limit toxic effects of therapy. These guidance statements have been generated based on review of the available literature, indicating that children with PRD do not appear to be at increased risk for susceptibility to SARS-CoV-2 infection. The purpose of this document is to help guide the management of patients with PRD during the COVID-19 pandemic and to support shared decision making between providers and individual patients and families. The statements should be used to This article is protected by copyright. All rights reserved supplement clinical judgement, recognizing that specific clinical scenarios may vary by individual patient. There are several strengths to be noted about the effort to create this clinical guidance document. The panel of experts on this task force reflect a multi-disciplinary collaboration, with specialists in pediatric rheumatology (both ACR and Association of Rheumatology Professionals (ARP) members), pediatric infectious disease and adult rheumatology, with a myriad of clinical expertise and interests. The task force was developed with intent to include experts from geographic locations across the United States (with varying degrees of SARS-CoV-2 community transmission) and those who treat patients with diverse demographics and socioeconomic status, to account for the spectrum of clinical disease seen in COVID-19. In addition, in response to the urgent need for clinical guidance during the COVID-19 pandemic, the task force generated statements over a compressed timeline, while maintaining a well-established method of consensus building, to ensure rapid dissemination of clinical recommendations. There are also limitations in this effort. Although an extensive review of the medical literature was performed to generate a detailed evidence report, it should be reiterated that this was a nonsystematic review of the literature with limited evidence. Although not formally assessed, evidence was generally of low quality, and not all sources were peer reviewed. The expert opinions and experience of task force members helped inform guidance. Thus, this guidance document does not follow the rigorous guideline methodology routinely used by the ACR when formal clinical practice guidelines are generated. Furthermore, current published evidence primarily reflects pediatric outcomes in the setting of school closures. Ongoing evaluation of outcomes for children with PRD in areas where schools reopen will be critically important in assessing risk. Finally, there are a few distinctions to be noted between our recommendations and those put forth in the ACR guidance for the management of adult patients with RD (2). Recognizing that children tend to have more mild manifestations of COVID-19, our task force recommended to continue current ongoing management of PRD (with modifications to glucocorticoid therapy as noted), even in the presence of exposure to SARS-CoV-2 or asymptomatic COVID-19. Our task force had the distinct advantage of more recent literature to support the notion that patients with PRD, on or off immunomodulatory therapy, do not appear to be at risk for increased likelihood of contracting This article is protected by copyright. All rights reserved COVID-19 or having worse outcomes, as compared to the general population. In addition, our task force agreed that selective inhibition of IL-1 is likely to be safe in the setting of infection from SARS-CoV-2 and may provide additional benefit in the management of COVID-19; thus, may be continued, even in symptomatic cases. As our knowledge regarding COVID-19 in children with PRD continues to expand, this document will be reviewed and modified as necessary to provide the most accurate and up to date guidance for rheumatology providers who treat children with PRD. This article is protected by copyright. All rights reserved For patients with PRD with active arthritis, intra-articular glucocorticoid injections may be administered. For patients with stable PRD, previously stable laboratory markers, on stable doses of cDMARDs, bDMARDs and/or tsDMARDs, extending the laboratory testing interval for monitoring medication toxicity may be considered to reduce potential exposure to SARS-CoV-2 during periods of increased community transmission. Laboratory monitoring for disease activity should be continued as per standard practice to ensure adequate assessment and control of underlying disease. De-escalation of therapy may be continued as planned in patients with PRD after considering the potential risks of disease flare and barriers to follow up during the pandemic. This article is protected by copyright. All rights reserved Glucocorticoids may be continued, using the lowest dose possible to control underlying disease. For patients with non-life and/or organ threatening PRD, initiation of high dose oral or intravenous glucocorticoids should be delayed for 1-2 weeks, if deemed safe by the treating provider*. For patients with PRD with life and/or organ threatening manifestations PRD, initiation of high dose oral or intravenous glucocorticoids should not be delayed*. This article is protected by copyright. All rights reserved Cyclophosphamide or rituximab may be continued, if necessary, to control underlying disease. Glucocorticoids should be continued, using the lowest dose possible to control underlying disease and avoid adrenal insufficiency. Glucocorticoids should be continued, with an effort to reduce the dose to the lowest dose possible to control underlying disease and avoid adrenal insufficiency. NSAIDs -non-steroidal anti-inflammatory drugs, HCQ -hydroxychloroquine, ACEi-angiotensinconverting enzyme inhibitor, ARB-angiotensin II receptor blocker, DMARDs -disease modifying anti-rheumatic drugs, cDMARDs -conventional DMARDs, bDMARDs -biologic DMARDs, tsDMARDs -targeted synthetic DMARDs * High dose oral glucocorticoids (>2 mg/kg/day prednisone equivalent) or intravenous "pulse" glucocorticoids (>10 mg/kg/day methylprednisolone equivalent) ** Defined as an interaction with a person known to have COVID-19 for more than 15 minutes at a distance of less than 6 feet without masking of both parties Accepted Article People who are immunocompromised American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol Septic shock presentation in adolescents with COVID-19 Severe COVID-19 in Children and Young Adults in the Washington, DC Metropolitan Region Viral and host factors related to the clinical outcome of COVID-19 US Agency for Health Care Policy and Research Office of the Forum for Quality and Effectiveness in Health Care clinical practice guideline development: methodology perspectives US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research The reproducibility of a method to identify the overuse and underuse of medical procedures Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies Absence of severe complications from SARS-CoV-2 infection in children with rheumatic diseases treated with biologic drugs Childhood Rheumatic Diseases and COVID-19 Pandemic: An Intriguing Linkage and a New Horizon Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs COVID-19 -Considerations for the paediatric rheumatologist Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic The severity of COVID-19 in children on immunosuppressive medication ) from the Paediatric IBD Porto Group of European Society of Paediatric Gastroenterology, Hepatology, and Nutrition Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 (COVID-19) at a Tertiary Care Medical Center in New York City. J Pediatr. 2020. 17. Patient experience survey updates Guidance on Preparing Workplaces for COVID-19. US Department of Labor Occupational Safety and Health Administration Challenges of "Return to Work" in an Ongoing Pandemic Coronavirus Disease 2019: Test for Past Infection Operating procedures for pediatric telehealth. American Telemedicine Association American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis Addressing mental health in pediatric rheumatology. Current Treatment Options in Rheumatology Depressive and anxiety symptom prevalence in childhoodonset systemic lupus erythematosus: A systematic review Depression And Anxiety In Patients With Juvenile Idiopathic Arthritis: Current Insights And Impact On Quality Of Life, A Systematic Review Coronavirus Disease 2019: Coping with Stress Protecting the psychological health of children through effective communication about COVID-19 Accepted Article This article is protected by copyright. All rights reserved 32. COVID-19 related mental health resources for children National Federation of Families for Children's Mental Health COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country The Question of Whether to Remain on Therapy for Chronic Rheumatic Diseases in the Setting of the Covid-19 Pandemic COVID-19 infection and rheumatoid arthritis: Faraway, so close Misguided drug advice for COVID-19 FDA advises patients on use of non-steroidal anti-inflammatory drugs (NSAIDs) for COVID Food and Drug Administration 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort Accepted Article This article is protected by copyright. All rights reserved 43 Serious infections among adult Medicaid beneficiaries with systemic lupus erythematosus and lupus nephritis Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications Lymphopenia as risk factor for development of severe infections in patients with systemic lupus erythematosus: a case-control study Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID COVID-19 epidemiology, transmission and insights from global registry data Recovery of the hypothalamic-pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Accepted Article This article is protected by copyright. All rights reserved initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features COVID-19) in Zhejiang, China: an observational cohort study The different clinical characteristics of corona virus disease cases between children and their families in China -the character of children with COVID-19 Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding Epidemiology of COVID-19 Among Children in China Incidence of COVID-19 in Pediatric Surgical Patients Among 3 US Children's Hospitals. JAMA Surg. 2020. 61. Coronavirus 2019: When you can be around others ?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Silencing the cytokine storm: the Effective treatment of severe COVID-19 patients with tocilizumab Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial Baricitinib as potential treatment for 2019-nCoV acute respiratory disease The emerging safety profile of JAK inhibitors in rheumatic disease Accepted Article